Dataset: Expression data from Bone-Marrow Mesenchymal Stromal Cells (BM-MSC) from Follicular Lymphoma patient (FL) or Healthy Donor (HD).
Human bone marrow mesenchymal stromal cells (BM-MSC) could be committed toward a functional lymphoid-like stroma by a combination of...
Human bone marrow mesenchymal stromal cells (BM-MSC) could be committed toward a functional lymphoid-like stroma by a combination of TNFalpha (TNF) and Lymphotoxin alpha1/beta2 (LT) (Amé-Thomas et al Blood 2007). Bone marrow and lymph node stromal cells support FL malignant cell recruitment and growth in particular after comittment to a lymphoid-like differentiation in vitro. In addition, more than 70% of FL patients exhibit a bone marrow involvment at diagnosis. We delineate using Affymetrix U133+2.0 microarrays the gene expression profile of BM-MSC obtained from FL patients (FL-MSC) and age-matched healthy donors (HD-MSC) in order to identify a specific FL-MSC signature. In addition, we used Affymetrix microarrays to define the gene expression signature of lymphoid-like stromal cells obtained from HD-MSC by treatment with TNF/LT in vitro. This TNF/LT signature was then used to interpret the gene expression profile of FL-MSC. GEP was performed on 10 BM-MSC from FL patients and 6 from healthy donors, treated or not with TNF(10 ng/mL)/LT(100ng/mL)
- Species:
- human
- Samples:
- 28
- Source:
- E-GEOD-35331
- Updated:
- Dec.12, 2014
- Registered:
- Sep.19, 2014
Sample | GROWTH PROTOCOL | AGE (Y) | PATHOLOGY | TREATMENT | GENDER |
---|---|---|---|---|---|
GSM866168 | alphaMEM+10%FBS+FGF2(1ng/mL) | 55 | Healthy donor | Untreated | male |
GSM866169 | alphaMEM+10%FBS+FGF2(1ng/mL) | 53 | Healthy donor | Untreated | male |
GSM866170 | alphaMEM+10%FBS+FGF2(1ng/mL) | 30 | Healthy donor | Untreated | male |
GSM86617 | alphaMEM+10%FBS+FGF2(1ng/mL) | 68 | Healthy donor | Untreated | female |
GSM866169 | alphaMEM+10%FBS+FGF2(1ng/mL) | 53 | Healthy donor | Untreated | male |
GSM866173 | alphaMEM+10%FBS+FGF2(1ng/mL) | 78 | Healthy donor | Untreated | female |
GSM866174 | alphaMEM+10%FBS+FGF2(1ng/mL) | 68 | Follicular Lymphoma patient | Untreated | male |
GSM866175 | alphaMEM+10%FBS+FGF2(1ng/mL) | 55 | Follicular Lymphoma patient | Untreated | male |
GSM866176 | alphaMEM+10%FBS+FGF2(1ng/mL) | 76 | Follicular Lymphoma patient | Untreated | male |
GSM866177 | alphaMEM+10%FBS+FGF2(1ng/mL) | 53 | Follicular Lymphoma patient | Untreated | female |
GSM866178 | alphaMEM+10%FBS+FGF2(1ng/mL) | 73 | Follicular Lymphoma patient | Untreated | male |
GSM866179 | alphaMEM+10%FBS+FGF2(1ng/mL) | 61 | Follicular Lymphoma patient | Untreated | male |
GSM866180 | alphaMEM+10%FBS+FGF2(1ng/mL) | 47 | Follicular Lymphoma patient | Untreated | male |
GSM86618 | alphaMEM+10%FBS+FGF2(1ng/mL) | 56 | Follicular Lymphoma patient | Untreated | male |
GSM866182 | alphaMEM+10%FBS+FGF2(1ng/mL) | 42 | Follicular Lymphoma patient | Untreated | male |
GSM866183 | alphaMEM+10%FBS+FGF2(1ng/mL) | 66 | Follicular Lymphoma patient | Untreated | female |
GSM866168 | alphaMEM+10%FBS+FGF2(1ng/mL) | 55 | Healthy donor | Untreated | male |
GSM866169 | alphaMEM+10%FBS+FGF2(1ng/mL) | 53 | Healthy donor | Untreated | male |
GSM866170 | alphaMEM+10%FBS+FGF2(1ng/mL) | 30 | Healthy donor | Untreated | male |
GSM86617 | alphaMEM+10%FBS+FGF2(1ng/mL) | 68 | Healthy donor | Untreated | female |
GSM866169 | alphaMEM+10%FBS+FGF2(1ng/mL) | 53 | Healthy donor | Untreated | male |
GSM866173 | alphaMEM+10%FBS+FGF2(1ng/mL) | 78 | Healthy donor | Untreated | female |
GSM866190 | RPMI1640+10%FBS | 55 | Healthy donor | Stimulated by TNF+LT for 3 days | male |
GSM86619 | RPMI1640+10%FBS | 53 | Healthy donor | Stimulated by TNF+LT for 3 days | male |
GSM866192 | RPMI1640+10%FBS | 30 | Healthy donor | Stimulated by TNF+LT for 3 days | male |
GSM866193 | RPMI1640+10%FBS | 68 | Healthy donor | Stimulated by TNF+LT for 3 days | female |
GSM86619 | RPMI1640+10%FBS | 53 | Healthy donor | Stimulated by TNF+LT for 3 days | male |
GSM866195 | RPMI1640+10%FBS | 78 | Healthy donor | Stimulated by TNF+LT for 3 days | female |